Beukers M W, den Dulk H, van Tilburg E W, Brouwer J, Ijzerman A P
Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands.
Mol Pharmacol. 2000 Dec;58(6):1349-56. doi: 10.1124/mol.58.6.1349.
Adenosine A(2B) receptors are known as low-affinity receptors due to their modest-to-negligible affinity for adenosine and prototypic agonists. Despite numerous synthetic efforts, 5'-N-ethylcarboxamidoadenosine (NECA) still is the reference agonist, albeit nonselective for this receptor. In our search for higher affinity agonists, we developed decision schemes to select amino acids for mutation to the corresponding residues in the most homologous, higher affinity, human A(2A) receptor. One scheme exploited knowledge on sequence alignments and modeling data and yielded three residues, V11, L58, and F59, mutation of which did not affect agonist affinity. The second scheme combined knowledge on sequence alignments and mutation data and pointed to Ala12 and Asn273. Mutation of Ala12 to threonine did not affect the affinity for NECA, (R)-N(6)-(phenylisopropyl)adenosine (R-PIA), and 2Cl Ado. The affinity of the N273Y mutant for NECA and R-PIA and for the antagonists xanthine amine congener (XAC), ZM241385, and SCH58261 was also unaltered. However, this mutant had a slightly increased affinity for a 2-substituted adenosine derivative, CGS21680. This prompted us to investigate other 2-substituted adenosines, with selectivity and high affinity for A(2A) receptors. All four compounds tested had improved affinity for the N273Y receptor. Of these, 2-(1-hexynyl)adenosine had submicromolar affinity for the N273Y receptor, 0.18 +/- 0.10 microM, with a 61-fold affinity gain over the wt receptor. In addition, the non-NECA analog (S)-PHP adenosine had an affinity of 1.7 +/- 0.5 microM for the wt receptor. The high affinity of (S)-PHP adenosine for the wt receptor suggests that further modifications at the 2-position may yield agonists with even higher affinity for A(2B) receptors.
腺苷A(2B)受体因其对腺苷和原型激动剂的亲和力适中至可忽略不计而被称为低亲和力受体。尽管进行了大量的合成努力,但5'-N-乙基甲酰胺基腺苷(NECA)仍然是参考激动剂,尽管它对该受体没有选择性。在我们寻找更高亲和力激动剂的过程中,我们开发了决策方案,以选择氨基酸进行突变,使其对应于最同源、亲和力更高的人A(2A)受体中的相应残基。一种方案利用了序列比对和建模数据的知识,得到了三个残基V11、L58和F59,对其进行突变并不影响激动剂亲和力。第二种方案结合了序列比对和突变数据的知识,指向了Ala12和Asn273。将Ala12突变为苏氨酸并不影响对NECA、(R)-N(6)-(苯异丙基)腺苷(R-PIA)和2Cl Ado的亲和力。N273Y突变体对NECA和R-PIA以及拮抗剂黄嘌呤胺类似物(XAC)、ZM241385和SCH58261的亲和力也未改变。然而,该突变体对一种2-取代腺苷衍生物CGS21680的亲和力略有增加。这促使我们研究其他对A(2A)受体具有选择性和高亲和力的2-取代腺苷。所测试的所有四种化合物对N273Y受体的亲和力都有所提高。其中,2-(1-己炔基)腺苷对N273Y受体的亲和力为亚微摩尔级,为0.18±0.10微摩尔,与野生型受体相比亲和力提高了61倍。此外,非NECA类似物(S)-PHP腺苷对野生型受体的亲和力为1.7±0.5微摩尔。(S)-PHP腺苷对野生型受体的高亲和力表明,在2-位进行进一步修饰可能会产生对A(2B)受体具有更高亲和力的激动剂。